Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)
Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.
This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.
Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Consolidated pathway for early-stage engagement with the regulator for innovative medicines and medical devices, focusing on scientific and regulatory advice.
Facilitates proactive discussion with regulators on pharmacovigilance planning and risk management strategies early in the product development lifecycle for innovative products.
Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.
The MHRA Innovation Accelerator provides a consolidated pathway for early-stage engagement with the regulator and offers scientific and regulatory guidance to developers of innovative medical products, facilitating discussion on pharmacovigilance and risk management strategies.
What changed: Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.
Why it matters: This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.
Practical implication: Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
